company background image

AbbVie NYSE:ABBV Stock Report

Last Price


Market Cap







21 May, 2022


Company Financials +
ABBV fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance4/6
Financial Health3/6

ABBV Stock Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.

AbbVie Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AbbVie
Historical stock prices
Current Share PriceUS$151.01
52 Week HighUS$175.91
52 Week LowUS$105.56
1 Month Change-4.74%
3 Month Change4.85%
1 Year Change30.05%
3 Year Change88.62%
5 Year Change128.60%
Change since IPO331.46%

Recent News & Updates

May 08

AbbVie: Buy, Hold, Or Sell After Q1 Results?

AbbVie is a very high-quality company with strong cash flows, exactly the type of company you want to own if we fall into a recession. But it recently posted disappointing results that caused a selloff. Despite near-term pain, the long-term thesis remains strong.

Shareholder Returns

ABBVUS BiotechsUS Market

Return vs Industry: ABBV exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: ABBV exceeded the US Market which returned -12.9% over the past year.

Price Volatility

Is ABBV's price volatile compared to industry and market?
ABBV volatility
ABBV Average Weekly Movement3.6%
Biotechs Industry Average Movement12.4%
Market Average Movement7.9%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ABBV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ABBV's weekly volatility (4%) has been stable over the past year.

About the Company

201250,000Rick Gonzalez

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.

AbbVie Fundamentals Summary

How do AbbVie's earnings and revenue compare to its market cap?
ABBV fundamental statistics
Market CapUS$266.85b
Earnings (TTM)US$12.41b
Revenue (TTM)US$56.73b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABBV income statement (TTM)
Cost of RevenueUS$17.14b
Gross ProfitUS$39.58b
Other ExpensesUS$27.18b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)7.02
Gross Margin69.78%
Net Profit Margin21.87%
Debt/Equity Ratio451.4%

How did ABBV perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is AbbVie undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: ABBV ($151.01) is trading below our estimate of fair value ($341.33)

Significantly Below Fair Value: ABBV is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: ABBV is poor value based on its PE Ratio (21.5x) compared to the US Biotechs industry average (15.1x).

PE vs Market: ABBV is poor value based on its PE Ratio (21.5x) compared to the US market (15.3x).

Price to Earnings Growth Ratio

PEG Ratio: ABBV's earnings are forecast to decline next year, so we can't calculate its PEG ratio.

Price to Book Ratio

PB vs Industry: ABBV is overvalued based on its PB Ratio (16.4x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is AbbVie forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABBV's earnings are forecast to decline over the next 3 years (-0.3% per year).

Earnings vs Market: ABBV's earnings are forecast to decline over the next 3 years (-0.3% per year).

High Growth Earnings: ABBV's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ABBV's revenue (0.7% per year) is forecast to grow slower than the US market (7.8% per year).

High Growth Revenue: ABBV's revenue (0.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABBV's Return on Equity is forecast to be very high in 3 years time (82.3%).

Past Performance

How has AbbVie performed over the past 5 years?

Past Performance Score


Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ABBV has a large one-off loss of $3.7B impacting its March 31 2022 financial results.

Growing Profit Margin: ABBV's current net profit margins (21.9%) are higher than last year (10.1%).

Past Earnings Growth Analysis

Earnings Trend: ABBV's earnings have grown by 9% per year over the past 5 years.

Accelerating Growth: ABBV's earnings growth over the past year (144%) exceeds its 5-year average (9% per year).

Earnings vs Industry: ABBV earnings growth over the past year (144%) exceeded the Biotechs industry 96.9%.

Return on Equity

High ROE: Whilst ABBV's Return on Equity (76.54%) is outstanding, this metric is skewed due to their high level of debt.

Financial Health

How is AbbVie's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ABBV's short term assets ($26.5B) do not cover its short term liabilities ($32.5B).

Long Term Liabilities: ABBV's short term assets ($26.5B) do not cover its long term liabilities ($94.4B).

Debt to Equity History and Analysis

Debt Level: ABBV's net debt to equity ratio (405%) is considered high.

Reducing Debt: ABBV's debt to equity ratio has reduced from 744.8% to 451.4% over the past 5 years.

Debt Coverage: ABBV's debt is well covered by operating cash flow (31%).

Interest Coverage: ABBV's interest payments on its debt are well covered by EBIT (8.7x coverage).

Balance Sheet


What is AbbVie current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: ABBV's dividend (3.73%) is higher than the bottom 25% of dividend payers in the US market (1.58%).

High Dividend: ABBV's dividend (3.73%) is low compared to the top 25% of dividend payers in the US market (4.11%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, ABBV has been paying a dividend for less than 10 years.

Growing Dividend: ABBV's dividend payments have increased, but the company has only paid a dividend for 9 years.

Earnings Payout to Shareholders

Earnings Coverage: At its current payout ratio (77.3%), ABBV's payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (45.2%), ABBV's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Rick Gonzalez (67 yo)





Mr. Richard A. Gonzalez, also known as Rick, serves as the Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of...

CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD23.91M) is above average for companies of similar size in the US market ($USD13.34M).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: ABBV's management team is considered experienced (3.5 years average tenure).

Board Members

Experienced Board: ABBV's board of directors are considered experienced (9.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

AbbVie Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: AbbVie Inc.
  • Ticker: ABBV
  • Exchange: NYSE
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$266.851b
  • Shares outstanding: 1.77b
  • Website:

Number of Employees


  • AbbVie Inc.
  • 1 North Waukegan Road
  • North Chicago
  • Illinois
  • 60064-6400
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.